Initiating Free Research Reports on Pulmatrix and Three Other Biotech Equities

Stock Research Monitor: PTI, PRTA, and PTCT

LONDON, UK / ACCESSWIRE / June 4, 2018 / If you want a free Stock Review on PULM sign up now at www.wallstequities.com/registration. On Friday, the NASDAQ Composite ended the day at 7,554.33, up 1.51%; the Dow Jones Industrial Average edged 0.90% higher, to finish at 24,635.21; and the S&P 500 closed at 2,734.62, gaining 1.08%. Gains were broad based as eight out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Proteostasis Therapeutics Inc. (NASDAQ: PTI), Prothena Corp. PLC (NASDAQ: PRTA), PTC Therapeutics Inc. (NASDAQ: PTCT), and Pulmatrix Inc. (NASDAQ: PULM). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Proteostasis Therapeutics

Cambridge, Massachusetts headquartered Proteostasis Therapeutics Inc.’s stock finished Friday’s session 3.93% higher at $5.03 with a total trading volume of 402,256 shares. The stock has gained 50.15% over the past three months and 14.84% in the previous twelve months. The Company’s shares are trading above their 200-day moving average by 39.97%. Moreover, shares of Proteostasis Therapeutics, which discovers and develops novel therapeutics to treat cystic fibrosis and other diseases caused by an imbalance in the proteostasis network, have a Relative Strength Index (RSI) of 51.38. Get the full research report on PTI for free by clicking below at:

www.wallstequities.com/registration/?symbol=PTI

Prothena

Shares in Dun Laoghaire, Ireland headquartered Prothena Corp. PLC rose 1.48%, ending last Friday’s session at $13.69 with a total trading volume of 637,109 shares. The stock has gained 3.95% in the past month. The Company’s shares are trading below their 50-day moving average by 44.11%. Moreover, shares of Prothena, which focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories, have an RSI of 28.48.

On May 21st, 2018, research firm Barclays downgraded the Company’s stock rating from ‘Equal Weight’ to ‘Underweight’ while revising its previous target price from $14 a share to $12 a share. Gain free access to the research report on PRTA at:

www.wallstequities.com/registration/?symbol=PRTA

PTC Therapeutics

On Friday, South Plainfield, New Jersey headquartered PTC Therapeutics Inc.’s stock saw a rise of 6.52%, to close the day at $36.11. A total volume of 1.78 million shares was traded, which was higher than their three months average volume of 906.47 thousand shares. The Company’s shares have advanced 19.06% in the last month, 40.34% in the previous three months, and 188.19% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 24.63% and 60.91%, respectively. Additionally, shares of PTC Therapeutics, which focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders, have an RSI of 75.38. Signing up today on Wall St. Equities will give you access to the latest report on PTCT at:

www.wallstequities.com/registration/?symbol=PTCT

Pulmatrix

Shares in Lexington, Massachusetts headquartered Pulmatrix Inc. ended the day 3.33% higher at $0.49. A total volume of 5.10 million shares was traded, which was above their three months average volume of 864.16 thousand shares. The stock has gained 5.15% in the last month. The Company’s shares are trading below their 50-day moving average by 7.59%. Furthermore, shares of Pulmatrix, which develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology, have an RSI of 60.39. Register now for today’s free coverage on PULM at:

www.wallstequities.com/registration/?symbol=PULM

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 501637